STOCK TITAN

Aprea Therapeutics, Inc. - $APRE STOCK NEWS

Welcome to our dedicated page for Aprea Therapeutics news (Ticker: $APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aprea Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aprea Therapeutics's position in the market.

Rhea-AI Summary
Aprea Therapeutics, Inc. (Nasdaq: APRE) provided a corporate update on their pipeline of DNA Damage Response (DDR) anti-cancer agents, highlighting the progress made in the ongoing Phase 1/2a clinical trial of ATRN-119 and the submission of the IND for APR-1051, a next-generation WEE1 inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
Rhea-AI Summary
Aprea Therapeutics, Inc. (Nasdaq: APRE) reported financial results for the three and nine months ended September 30, 2023, and provided a business update. The company highlighted the progress of its ATR inhibitor, ATRN-119, in solid tumors, and its WEE1 inhibitor, ATRN-1051. Key milestones include the completion of dose escalation for ATRN-119 in 1Q 2024 and the initiation of the dose expansion study in 2Q 2024. Financially, the company reported cash and cash equivalents of $25.4 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
-
Rhea-AI Summary
Aprea Therapeutics will host a KOL event on October 31, 2023, featuring Dr. Fiona Simpkins and Dr. Timothy A. Yap. They will discuss treatments and investigational drugs for patients with advanced solid tumors. Aprea will also discuss its Phase 1/2a study evaluating ATRN-119 and its pre-clinical WEE1 inhibitor, ATRN-1051. A live Q&A session will follow the presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences
Rhea-AI Summary
Aprea Therapeutics announces two poster presentations at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Aprea is developing ATRN-119 for solid tumor indications and ATRN-1051, with an IND submission expected in Q4 2023. Oren Gilad, CEO, will attend the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
-
Rhea-AI Summary
Aprea Therapeutics announces positive preclinical data for ATRN-1051 in ovarian cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
-
Rhea-AI Summary
Aprea Therapeutics to present corporate overview at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
conferences
Rhea-AI Summary
Aprea Therapeutics appoints Dr. Jean-Pierre Bizzari to its Board of Directors and names Dr. Richard Peters as new Chairman of the Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Aprea Therapeutics, Inc. reported financial results for Q2 2023, with cash and cash equivalents of $27.7 million. The company continues to make progress in its ATR inhibitor program, with enrollment ongoing in the Phase 1/2a trial of ATRN-119. The company expects to report initial interim safety, tolerability, and pharmacokinetic data in Q4 2023. In the WEE1 inhibitor program, IND enabling studies with ATRN-1051 are underway, with an IND filing anticipated by the end of 2023. Gabriela Gruia, M.D., has been appointed to the Board of Directors. The company reported an operating loss of $3.7 million for Q2 2023, compared to $98.5 million for the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
conferences
Aprea Therapeutics, Inc.

Nasdaq:APRE

APRE Rankings

APRE Stock Data

28.62M
4.19M
11.67%
17.7%
1.95%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DOYLESTOWN

About APRE

annan naturvetenskaplig och teknisk forskning och utveckling